JP2023145620A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023145620A5 JP2023145620A5 JP2023122841A JP2023122841A JP2023145620A5 JP 2023145620 A5 JP2023145620 A5 JP 2023145620A5 JP 2023122841 A JP2023122841 A JP 2023122841A JP 2023122841 A JP2023122841 A JP 2023122841A JP 2023145620 A5 JP2023145620 A5 JP 2023145620A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- oligonucleotides
- oligonucleotide
- same
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762514769P | 2017-06-02 | 2017-06-02 | |
| US201762514771P | 2017-06-02 | 2017-06-02 | |
| US62/514,769 | 2017-06-02 | ||
| US62/514,771 | 2017-06-02 | ||
| US201862656949P | 2018-04-12 | 2018-04-12 | |
| US62/656,949 | 2018-04-12 | ||
| US201862670709P | 2018-05-11 | 2018-05-11 | |
| US201862670686P | 2018-05-11 | 2018-05-11 | |
| US62/670,709 | 2018-05-11 | ||
| US62/670,686 | 2018-05-11 | ||
| JP2019566651A JP2020522510A (ja) | 2017-06-02 | 2018-06-01 | オリゴヌクレオチド組成物及びその使用方法 |
| PCT/US2018/035687 WO2018223056A1 (en) | 2017-06-02 | 2018-06-01 | Oligonucleotide compositions and methods of use thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566651A Division JP2020522510A (ja) | 2017-06-02 | 2018-06-01 | オリゴヌクレオチド組成物及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023145620A JP2023145620A (ja) | 2023-10-11 |
| JP2023145620A5 true JP2023145620A5 (enExample) | 2024-04-05 |
Family
ID=64456312
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566651A Pending JP2020522510A (ja) | 2017-06-02 | 2018-06-01 | オリゴヌクレオチド組成物及びその使用方法 |
| JP2023122841A Pending JP2023145620A (ja) | 2017-06-02 | 2023-07-27 | オリゴヌクレオチド組成物及びその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566651A Pending JP2020522510A (ja) | 2017-06-02 | 2018-06-01 | オリゴヌクレオチド組成物及びその使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11603532B2 (enExample) |
| EP (1) | EP3630199A4 (enExample) |
| JP (2) | JP2020522510A (enExample) |
| CN (2) | CN111050806A (enExample) |
| WO (1) | WO2018223056A1 (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102712879B1 (ko) | 2012-07-13 | 2024-10-04 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| JP6268157B2 (ja) | 2012-07-13 | 2018-01-24 | 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ | 不斉補助基 |
| EP4137572A1 (en) | 2014-01-16 | 2023-02-22 | Wave Life Sciences Ltd. | Chiral design |
| RU2708237C2 (ru) | 2014-08-22 | 2019-12-05 | Общество с ограниченной ответственностью "НооГен" | Модифицированные олигонуклеотиды и способ их получения |
| EP3277811B1 (en) | 2015-04-03 | 2020-12-23 | University of Massachusetts | Fully stabilized asymmetric sirna |
| MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| CA2995110A1 (en) | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| SG10201912902TA (en) | 2015-10-09 | 2020-02-27 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods thereof |
| WO2017132669A1 (en) | 2016-01-31 | 2017-08-03 | University Of Massachusetts | Branched oligonucleotides |
| MA43822A (fr) | 2016-03-13 | 2018-11-28 | Wave Life Sciences Ltd | Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides |
| MA45270A (fr) | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| EP3463386A4 (en) | 2016-06-03 | 2020-03-04 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDES, COMPOSITIONS AND ASSOCIATED METHODS |
| US10988763B2 (en) | 2016-06-22 | 2021-04-27 | Proqr Therapeutics Ii B.V. | Single-stranded RNA-editing oligonucleotides |
| PL3507366T3 (pl) | 2016-09-01 | 2021-05-04 | Proqr Therapeutics Ii B.V. | Chemicznie modyfikowane jednoniciowe oligonukleotydy edytujące rna |
| US11873316B2 (en) | 2016-11-23 | 2024-01-16 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| JOP20190215A1 (ar) | 2017-03-24 | 2019-09-19 | Ionis Pharmaceuticals Inc | مُعدّلات التعبير الوراثي عن pcsk9 |
| JP2020522510A (ja) | 2017-06-02 | 2020-07-30 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド組成物及びその使用方法 |
| US11597927B2 (en) | 2017-06-02 | 2023-03-07 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| EP3642182A4 (en) | 2017-06-21 | 2020-12-09 | Wave Life Sciences Ltd. | COMPOUNDS, COMPOSITIONS AND SYNTHESIS METHODS |
| CA3064590A1 (en) | 2017-06-23 | 2018-12-27 | University Of Massachusetts | Two-tailed self-delivering sirna and related methods |
| WO2019032612A1 (en) | 2017-08-08 | 2019-02-14 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND ASSOCIATED METHODS |
| CR20200108A (es) * | 2017-09-11 | 2020-06-28 | Arrowhead Pharmaceuticals Inc | Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3) |
| KR20250123934A (ko) | 2017-09-18 | 2025-08-18 | 웨이브 라이프 사이언시스 리미티드 | 올리고뉴클레오티드 제조 기술 |
| EP3694530A4 (en) | 2017-10-12 | 2021-06-30 | Wave Life Sciences Ltd. | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
| UY38003A (es) * | 2017-12-12 | 2019-06-28 | Amgen Inc | Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas |
| KR20210018267A (ko) | 2018-05-07 | 2021-02-17 | 알닐람 파마슈티칼스 인코포레이티드 | 간외 전달 |
| CA3098624A1 (en) | 2018-05-11 | 2019-11-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| JP7618229B2 (ja) | 2018-08-10 | 2025-01-21 | ユニバーシティー オブ マサチューセッツ | Ｓｎｐを標的化する修飾オリゴヌクレオチド |
| JP7627042B2 (ja) | 2018-08-23 | 2025-02-05 | ユニバーシティー オブ マサチューセッツ | Ｏ－メチルリッチ完全安定化オリゴヌクレオチド |
| KR20210102932A (ko) * | 2018-12-10 | 2021-08-20 | 암젠 인크 | Pnpla3 발현을 억제하기 위한 rnai 작제물 및 이의 사용 방법 |
| GB201821269D0 (en) * | 2018-12-28 | 2019-02-13 | Nippon Shinyaku Co Ltd | Myostatin signal inhibitor |
| CN113614232A (zh) | 2019-01-18 | 2021-11-05 | 马萨诸塞大学 | 动态药代动力学修饰锚 |
| JP2022528840A (ja) | 2019-03-26 | 2022-06-16 | ユニバーシティ・オブ・マサチューセッツ | 安定性が増加した修飾オリゴヌクレオチド |
| WO2020205605A2 (en) * | 2019-03-29 | 2020-10-08 | University Of Massachusetts | OLIGONUCLEOTIDE-BASED MODULATION OF C9orf72 |
| US11629347B2 (en) | 2019-05-06 | 2023-04-18 | University Of Massachusetts | Anti-C9ORF72 oligonucleotides and related methods |
| US12024706B2 (en) | 2019-08-09 | 2024-07-02 | University Of Massachusetts | Modified oligonucleotides targeting SNPs |
| WO2021037205A1 (zh) * | 2019-08-29 | 2021-03-04 | 苏州瑞博生物技术股份有限公司 | 化合物和药物缀合物及其制备方法和用途 |
| US12365894B2 (en) | 2019-09-16 | 2025-07-22 | University Of Massachusetts | Branched lipid conjugates of siRNA for specific tissue delivery |
| JPWO2021070959A1 (enExample) * | 2019-10-11 | 2021-04-15 | ||
| AU2021213822A1 (en) | 2020-01-31 | 2022-09-22 | Avilar Therapeutics, Inc. | ASGPR-binding compounds for the degradation of extracellular proteins |
| EP4130266A4 (en) * | 2020-03-26 | 2025-10-08 | Nat Cerebral & Cardiovascular Ct | ANTISENSE NUCLEIC ACID TARGETING APOC3 |
| EP4126070A4 (en) | 2020-03-26 | 2024-07-24 | University Of Massachusetts | Synthesis of modified oligonucleotides with increased stability |
| US20230203484A1 (en) | 2020-05-22 | 2023-06-29 | Wave Life Sciences Ltd. | Double stranded oligonucleotide compositions and methods relating thereto |
| WO2022109030A1 (en) * | 2020-11-17 | 2022-05-27 | Skyhawk Therapeutics, Inc. | Rna-targeting splicing modifiers for treatment of pnpla3-associated conditions and diseases |
| EP4023658A1 (en) * | 2020-12-30 | 2022-07-06 | Fuchs, Merle | Modified nucleic acid conjugates |
| TW202308703A (zh) | 2021-05-03 | 2023-03-01 | 美商亞維拉治療公司 | 用於降解免疫球蛋白及其他蛋白質之有效asgpr結合化合物 |
| WO2022266486A2 (en) * | 2021-06-17 | 2022-12-22 | Sirnaomics, Inc. | Products and compositions |
| WO2023091644A2 (en) * | 2021-11-19 | 2023-05-25 | Wave Life Sciences Ltd. | Hsd17b13-related double stranded oligonucleotide compositions and methods relating thereto |
| EP4479535A1 (en) | 2022-02-14 | 2024-12-25 | ProQR Therapeutics II B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
| EP4555085A1 (en) | 2022-07-15 | 2025-05-21 | ProQR Therapeutics II B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
| WO2024013361A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Oligonucleotides for adar-mediated rna editing and use thereof |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| CN120476207A (zh) | 2022-11-24 | 2025-08-12 | ProQR治疗上市公司Ⅱ | 反义寡核苷酸治疗遗传性hfe血色素沉着症 |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| EP4630553A1 (en) | 2022-12-09 | 2025-10-15 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of cardiovascular disease |
| GB202300865D0 (en) | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
| WO2024175550A1 (en) | 2023-02-20 | 2024-08-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| WO2024206175A1 (en) | 2023-03-24 | 2024-10-03 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
| WO2024200472A1 (en) | 2023-03-27 | 2024-10-03 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
| AR132964A1 (es) | 2023-06-16 | 2025-08-13 | Proqr Therapeutics Ii Bv | Oligonucleótidos antisentido para el tratamiento de enfermedades neurodegenerativas |
| WO2025015335A1 (en) | 2023-07-13 | 2025-01-16 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| WO2025096809A1 (en) | 2023-10-31 | 2025-05-08 | Korro Bio, Inc. | Oligonucleotides comprising phosphoramidate internucleotide linkages |
| WO2025097061A1 (en) * | 2023-11-03 | 2025-05-08 | Avilar Therapeutics, Inc. | ApoB DEGRADING COMPOUNDS AND USES THEREOF |
| WO2025128799A1 (en) | 2023-12-12 | 2025-06-19 | Korro Bio, Inc. | Double-stranded rna-editing oligonucleotides and uses thereof |
| WO2025132708A1 (en) | 2023-12-20 | 2025-06-26 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of huntington's disease |
| WO2025153061A1 (zh) * | 2024-01-19 | 2025-07-24 | 云合智药（苏州）生物科技有限公司 | 用于抑制激活素iib型受体基因表达的核酸及其用途 |
| WO2025184301A1 (en) * | 2024-02-29 | 2025-09-04 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for dual inhibition of expression of apolipoprotein c-iii (apoc3) and proprotein convertase subtilisin kexin 9 (pcsk9), compositions thereof, and methods of use |
| GB202404661D0 (en) | 2024-04-02 | 2024-05-15 | Proqr Therapeutics Ii Bv | Antisense oligoncleotides for the treatment of liver disease |
| WO2025224230A1 (en) | 2024-04-25 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of fatty liver disease |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE151076T1 (de) | 1990-07-02 | 1997-04-15 | Hoechst Ag | Oligonucleotid-analoge mit terminalen 3'-3'-bzw. 5'-5'-internucleotidverknüpfungen |
| TW323284B (enExample) * | 1992-03-23 | 1997-12-21 | Novartis Ag | |
| US5216168A (en) | 1992-04-01 | 1993-06-01 | G. D. Searle & Co. | 2- and 3- amino and azido derivatives of 1,5-iminosugars |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| US20030138797A1 (en) | 2001-06-29 | 2003-07-24 | Micrologix Biotech Inc. | Nucleic acid-based compounds |
| WO2003025139A2 (en) | 2001-09-17 | 2003-03-27 | Mayo Foundation For Medical Education And Research | Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof |
| JP4348044B2 (ja) | 2002-02-12 | 2009-10-21 | 株式会社キラルジェン | 立体規則性の高いジヌクレオシドホスホロチオエートの製造法 |
| US8232383B2 (en) | 2002-02-20 | 2012-07-31 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| WO2004007718A2 (en) | 2002-07-10 | 2004-01-22 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Rna-interference by single-stranded rna molecules |
| AU2003261449A1 (en) | 2002-08-07 | 2004-02-25 | Compositions for rna interference and methods of use thereof | |
| US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| JP2005089441A (ja) | 2003-08-08 | 2005-04-07 | Toudai Tlo Ltd | 立体規則性の高いリン原子修飾ヌクレオチド類縁体の製造法 |
| WO2005028494A1 (ja) | 2003-09-02 | 2005-03-31 | Takeshi Wada | ５'-ホスフィチル化モノマーおよびh-ホスホネートオリゴヌクレオチド誘導体の製造方法 |
| WO2005023828A1 (ja) | 2003-09-02 | 2005-03-17 | Takeshi Wada | リボヌクレオチド又はリボヌクレオチド誘導体の製造方法 |
| MY145571A (en) * | 2003-12-19 | 2012-02-29 | Ciba Holding Inc | Fluorocarbon terminated oligo-and poly-carbonates as surface modifiers |
| JP4945129B2 (ja) | 2004-01-27 | 2012-06-06 | 株式会社キラルジェン | フルオラス担体およびそれを用いたオリゴヌクレオチド誘導体の製造方法 |
| WO2005085272A1 (ja) | 2004-03-05 | 2005-09-15 | Takeshi Wada | ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法 |
| JP4865544B2 (ja) | 2004-03-25 | 2012-02-01 | 株式会社キラルジェン | 立体規則性の高いリボヌクレオチド類縁体及びデオキシリボヌクレオチド類縁体の製造法 |
| EP1766010B1 (en) | 2004-06-28 | 2011-02-16 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| WO2006023880A2 (en) | 2004-08-23 | 2006-03-02 | Isis Pharmaceuticals, Inc. | Compounds and methods for the characterization of oligonucleotides |
| DE502005008153D1 (de) | 2005-11-23 | 2009-10-29 | Roche Diagnostics Gmbh | Polynukleotid mit Phosphatmimetikum |
| CN101663313B (zh) | 2007-04-18 | 2013-08-21 | 霍夫曼-拉罗奇有限公司 | 具有α-磷酸模拟物的核苷酸 |
| EP2358398A2 (en) * | 2008-10-24 | 2011-08-24 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
| US8883752B2 (en) * | 2008-10-24 | 2014-11-11 | Isis Pharmaceuticals, Inc. | 5′ and 2′ BIS-substituted nucleosides and oligomeric compounds prepared therefrom |
| CA2744987C (en) | 2008-12-02 | 2018-01-16 | Chiralgen, Ltd. | Method for the synthesis of phosphorus atom modified nucleic acids |
| EP2405921A4 (en) * | 2009-01-26 | 2013-05-22 | Protiva Biotherapeutics Inc | COMPOSITIONS AND METHODS FOR INACTIVATION OF APOLIPOPROTEIN C-III EXPRESSION |
| CA2767253A1 (en) | 2009-07-06 | 2011-01-13 | Ontorii, Inc. | Novel nucleic acid prodrugs and methods of use thereof |
| US8927513B2 (en) | 2009-07-07 | 2015-01-06 | Alnylam Pharmaceuticals, Inc. | 5′ phosphate mimics |
| CN102574888A (zh) | 2009-09-16 | 2012-07-11 | 株式会社启拉坚 | 用于rna及其衍生物的合成的新型保护基 |
| WO2011109427A2 (en) | 2010-03-01 | 2011-09-09 | Alnylam Pharmaceuticals, Inc. | Improving the biological activity of sirna through modulation of its thermodynamic profile |
| CN102918052A (zh) | 2010-03-05 | 2013-02-06 | 国立大学法人东京大学 | 硫代磷酸核糖核苷的制造方法 |
| JP2011184318A (ja) | 2010-03-05 | 2011-09-22 | Univ Of Tokyo | リボヌクレシドｈ−ボラノホスホネート |
| US20130156845A1 (en) * | 2010-04-29 | 2013-06-20 | Alnylam Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
| TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| WO2012037254A1 (en) | 2010-09-15 | 2012-03-22 | Alnylam Pharmaceuticals, Inc. | MODIFIED iRNA AGENTS |
| WO2012039448A1 (ja) | 2010-09-24 | 2012-03-29 | 株式会社キラルジェン | 不斉補助基 |
| WO2012073857A1 (ja) | 2010-11-30 | 2012-06-07 | 株式会社キラルジェン | ２'－ｏ－修飾ｒｎａ |
| SG194671A1 (en) | 2011-04-27 | 2013-12-30 | Isis Pharmaceuticals Inc | Modulation of apolipoprotein ciii (apociii) expression |
| MX344807B (es) * | 2011-06-21 | 2017-01-09 | Alnylam Pharmaceuticals Inc | Composiciones y metodos para inhibicion de genes para alipoproteina c-iii (apoc3). |
| WO2013009735A1 (en) * | 2011-07-13 | 2013-01-17 | Merck Sharp & Dohme Corp. | 5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| WO2013012758A1 (en) | 2011-07-19 | 2013-01-24 | Ontorii, Inc. | Methods for the synthesis of functionalized nucleic acids |
| JPWO2013089157A1 (ja) | 2011-12-12 | 2015-04-27 | 独立行政法人国立循環器病研究センター | オリゴヌクレオチド、およびオリゴヌクレオチドを有効成分として含有する高脂血症治療剤 |
| JP6268157B2 (ja) | 2012-07-13 | 2018-01-24 | 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ | 不斉補助基 |
| CN104684923B (zh) | 2012-07-13 | 2018-09-28 | 株式会社新日本科学 | 手性核酸佐剂 |
| KR102712879B1 (ko) | 2012-07-13 | 2024-10-04 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| CA2901119C (en) | 2013-02-14 | 2022-10-18 | Isis Pharmaceuticals, Inc. | Modulation of apolipoprotein c-iii (apociii) expression in lipoprotein lipase deficient (lpld) populations |
| US9127276B2 (en) | 2013-05-01 | 2015-09-08 | Isis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| JPWO2015108046A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
| US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| EP4137572A1 (en) * | 2014-01-16 | 2023-02-22 | Wave Life Sciences Ltd. | Chiral design |
| EP3960860A3 (en) * | 2014-02-11 | 2022-06-08 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
| CN106255755B (zh) * | 2014-05-01 | 2020-07-24 | Ionis制药公司 | 用于调节血管生成素样蛋白3表达的组合物和方法 |
| RU2708237C2 (ru) | 2014-08-22 | 2019-12-05 | Общество с ограниченной ответственностью "НооГен" | Модифицированные олигонуклеотиды и способ их получения |
| CA2968114A1 (en) * | 2014-11-17 | 2016-05-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
| JP2018510621A (ja) | 2015-02-13 | 2018-04-19 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | パタチン様ホスホリパーゼドメイン含有３（ＰＮＰＬＡ３）ｉＲＮＡ組成物およびその使用方法 |
| HRP20201200T1 (hr) * | 2015-04-03 | 2020-11-13 | University Of Massachusetts | OLIGONUKLEOTIDNI SPOJEVI ZA CILJANJE HUNTINGTIN mRNK |
| MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| EP3350328A1 (en) | 2015-09-14 | 2018-07-25 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof |
| SG10201912902TA (en) | 2015-10-09 | 2020-02-27 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods thereof |
| MA43822A (fr) | 2016-03-13 | 2018-11-28 | Wave Life Sciences Ltd | Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides |
| MA45270A (fr) | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| MA45290A (fr) | 2016-05-04 | 2019-03-13 | Wave Life Sciences Ltd | Procédés et compositions d'agents biologiquement actifs |
| SG10202101836TA (en) | 2016-05-24 | 2021-03-30 | Sarepta Therapeutics Inc | Processes for preparing phosphorodiamidate morpholino oligomers |
| EP3463386A4 (en) | 2016-06-03 | 2020-03-04 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDES, COMPOSITIONS AND ASSOCIATED METHODS |
| US20190264267A1 (en) | 2016-07-25 | 2019-08-29 | Wave Life Sciences Ltd. | Phasing |
| RU2016138168A (ru) | 2016-09-26 | 2018-03-29 | Оксфордский Университет | Аналоги олигонуклеотидов как средства коррекции сплайсинга для лечения мышечной дистрофии дюшена |
| US11873316B2 (en) | 2016-11-23 | 2024-01-16 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| RU2740501C2 (ru) | 2017-02-21 | 2021-01-14 | Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) | МОДИФИЦИРОВАННЫЕ ОЛИГОНУКЛЕОТИДЫ, АКТИВИРУЮЩИЕ РНКазу Н |
| JP2020522510A (ja) | 2017-06-02 | 2020-07-30 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド組成物及びその使用方法 |
| US20210198305A1 (en) | 2017-06-02 | 2021-07-01 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| US11597927B2 (en) | 2017-06-02 | 2023-03-07 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| EP3642182A4 (en) | 2017-06-21 | 2020-12-09 | Wave Life Sciences Ltd. | COMPOUNDS, COMPOSITIONS AND SYNTHESIS METHODS |
| CN110831951B (zh) | 2017-06-28 | 2023-10-27 | 罗氏创新中心哥本哈根有限公司 | 多重偶联和氧化方法 |
| WO2019032612A1 (en) | 2017-08-08 | 2019-02-14 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND ASSOCIATED METHODS |
| KR20250123934A (ko) | 2017-09-18 | 2025-08-18 | 웨이브 라이프 사이언시스 리미티드 | 올리고뉴클레오티드 제조 기술 |
| WO2019071028A1 (en) * | 2017-10-04 | 2019-04-11 | Avidity Biosciences Llc | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF |
| EP3694530A4 (en) | 2017-10-12 | 2021-06-30 | Wave Life Sciences Ltd. | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
| UY38003A (es) | 2017-12-12 | 2019-06-28 | Amgen Inc | Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas |
| IL277889B2 (en) | 2018-04-12 | 2025-01-01 | Wave Life Sciences Ltd | Oligonucleotide preparations and methods of using them |
| CA3098624A1 (en) | 2018-05-11 | 2019-11-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| TWI869213B (zh) | 2018-09-19 | 2025-01-01 | 美商Ionis製藥公司 | Pnpla3表現之調節劑 |
| WO2020118246A1 (en) | 2018-12-06 | 2020-06-11 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| CN113423385A (zh) | 2019-02-01 | 2021-09-21 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| AU2020241559A1 (en) | 2019-03-20 | 2021-11-11 | Wave Life Sciences Ltd. | Technologies useful for oligonucleotide preparation |
| US20220307019A1 (en) | 2019-03-25 | 2022-09-29 | National University Corporation Tokyo Medical And Dental University | Double-stranded nucleic acid complex and use thereof |
| AU2020261434A1 (en) | 2019-04-25 | 2021-11-11 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| AU2020262485A1 (en) | 2019-04-25 | 2021-11-11 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| AU2020267775A1 (en) | 2019-05-09 | 2021-12-02 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| MX2022004102A (es) | 2019-10-06 | 2022-04-26 | Wave Life Sciences Ltd | Composiciones de oligonucleotidos y metodos de uso de las mismas. |
| MX2022004101A (es) | 2019-10-06 | 2022-04-26 | Wave Life Sciences Ltd | Composiciones de oligonucleotidos y metodos de uso de las mismas. |
| TW202138559A (zh) | 2019-12-16 | 2021-10-16 | 美商阿尼拉製藥公司 | 含類ＰＡＴＡＴＩＮ磷脂酶結構域３（ＰＮＰＬＡ３）ｉＲＮＡ組成物及其使用方法 |
| CN115210377A (zh) | 2020-03-01 | 2022-10-18 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| IL296718A (en) | 2020-03-26 | 2022-11-01 | Arrowhead Pharmaceuticals Inc | RNAi agents for inhibiting expression of pnpla3, their pharmaceutical compositions and methods of use |
| EP4153604A4 (en) | 2020-05-22 | 2024-11-27 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS |
-
2018
- 2018-06-01 JP JP2019566651A patent/JP2020522510A/ja active Pending
- 2018-06-01 CN CN201880048436.4A patent/CN111050806A/zh active Pending
- 2018-06-01 EP EP18809849.5A patent/EP3630199A4/en active Pending
- 2018-06-01 CN CN202510680630.6A patent/CN120884604A/zh active Pending
- 2018-06-01 WO PCT/US2018/035687 patent/WO2018223056A1/en not_active Ceased
- 2018-06-01 US US16/618,010 patent/US11603532B2/en active Active
-
2022
- 2022-09-29 US US17/956,741 patent/US20240132894A1/en active Pending
-
2023
- 2023-07-27 JP JP2023122841A patent/JP2023145620A/ja active Pending